小猪视频app Health's BioReference Laboratories Introduces Scarlet Health鈩�, an In-Home Diagnostic Service to Expand Digital Health Access
Scarlet brings diagnostic service to patients' homes, offices and other preferred locations, delivering an on-demand, safe and convenient diagnostic experience for patients and healthcare providers
ELMWOOD PARK, N.J., Jan. 13, 2021 /PRNewswire/ --听BioReference听Laboratories,听Inc.,听an 小猪视频app Health company (NASDAQ:OPK), today introduced听鈩�,听an听in-home,听fully integrated digital听platform听providing听access to听on-demand diagnostic services. Scarlet has been designed similarly to听tools consumers use daily, in order听to听provide ease-of-use and ubiquitous conveniences.听
Backed by听BioReference's听national presence and infrastructure, with laboratory facilities听and professionals across the country,听Scarlet听delivers听an innovative, flexible,听mobile听alternative to听traditional patient service centers听or听other听draw听locations听when phlebotomy听and听other specimen collection听services are听needed.听
Patients will no longer need to听travel for laboratory services. Healthcare providers听will听secure听vital diagnostic information about听patients听reliably,听quickly and easily听to听enable a听faster diagnosis.听听
To听use听Scarlet's听convenient, secure听and safe approach to听mobile听specimen collection services, patients will听obtain听a link听after听visiting听or connecting virtually with听their听healthcare provider.听After confirming the services needed, a patient will听verify听their identity听and schedule a date and time, and choose their preferred听location听(i.e.,听at their office or home)听for听a听qualified healthcare professional to collect听their听test听specimen.听Patients will then听receive听real-time updates听and relevant information, such as learning听how to prepare for听the visit or track the healthcare professional's arrival. Specimens will be sent to听BioReference听for testing,听and听the听results听will be听securely听shared听online听with the patient and听their听ordering healthcare provider.听听
"Scarlet reimagines the delivery of health care, creating an accessible, consumer-centric approach to the way patients receive laboratory services," said听Richard Schwabacher, Senior Vice President of听Digital Health and Chief Digital Officer听for听BioReference听Laboratories.听"Scarlet is the听first of many digital health advances at听BioReference听that aim to increase flexibility and convenience for patients. We're proud to bring this kind of innovation and technology to patients and are looking forward to expanding access to听critical health care needs with听Scarlet."听听
Investment in telemedicine has more than doubled in the last year听to $1.6 billion, a dramatic acceleration attributable听to the COVID-19 pandemic听and the听growing demand for the tools and flexibility that digital health offers.1听Scarlet听provides a much-needed service that is efficient, secure, convenient, flexible, digitally enabled and easy to use,听providing听access to a variety of tests, from COVID-19 to chronic conditions,听and more.听听
"The future of health care is at home. We're听helping to make听in-home health care real for听millions of Americans听by bringing diagnostic听services听directly to the patient," said Jon R. Cohen, M.D., Executive Chairman of听BioReference听Laboratories.鈥�"According听to听PwC Health Research Institute Health's听2020听executive survey, 40% of healthcare providers cited laboratory听challenges听as a concern with听growing telehealth programs.听By adding just a few听key strokes to what healthcare providers are already doing, Scarlet听improves and encourages听patient-centered health care, utilizing听a similar听on-demand听format that patients use every day from the comfort of听their homes. With Scarlet,听BioReference听removes听a听disconnect between听telemedicine and traditional health care,听and revolutionizes听how healthcare is听provided."听
Scarlet听services听are currently available in听select markets.听For more information on听Scarlet, visit听.听听听听
About听BioReference听Laboratories, Inc.听
BioReference听provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions, and medical groups.听BioReference听offers test services that yield high-quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 120 M.D., Ph.D. and other professional level clinicians and scientists. With a leading position in the areas of genetics, women's health, maternal fetal medicine, oncology, and urology,听BioReference听and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine. For more information, visit .听
About 小猪视频app Health听听
小猪视频app is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit听.听
Cautionary Statement Regarding Forward-Looking Statements听
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning,听particularly听statements regarding BioReference's Scarlet Health mobile service,听the availability of听and demand for the service,听whether the service and the integrated platform will function or perform as designed,听the role and value of the听service to patients and听healthcare providers and whether the demand for at home health care will continue or increase as anticipated, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the 小猪视频app Health, Inc. Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in its other filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.听
References:听
听听听听听1.听听听 PwC Health Research Institute Health's 2020 executive survey听
View original content to download multimedia:
SOURCE BioReference Laboratories, Inc
Released January 13, 2021